TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30400340

Group type: EXPERIMENTAL
Intervention: Carbohydrate from bananas (BAN)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Carbohydrate from a 6% sugar beverage (SUG)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Water (WAT)
Number of subjects: 20
Study: 27136251

Group type: EXPERIMENTAL
Intervention: Pittsburgh Sleep Quality Index (PSQI) administered at baseline, 2, 6, and 12 months after transplant; 12-month PSQI categorized good versus poor sleepers.
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Female gender as a predictor of poor sleep quality.
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Correlation between poor sleep quality and mental HRQOL.
Number of subjects: 75
Study: 24931322

Group type: EXPERIMENTAL
Intervention: Vatreptacog alfa (80 μg kg(‐1), one to three doses)
Number of subjects: 72

Group type: COMPARATOR
Intervention: rFVIIa (90 μg kg(‐1), one to three doses)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Vatreptacog alfa
Number of subjects: 72
Study: 21625881

Group type: EXPERIMENTAL
Intervention: Exercise Group (EG)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 85
Study: 20449645

Group type: EXPERIMENTAL
Intervention: Knowledge-based measure of social information processing and anger management techniques
Number of subjects: 0
Study: 18630772

Group type: EXPERIMENTAL
Intervention: 2 microg/kg nitroglycerine
Number of subjects: 150

Group type: COMPARATOR
Intervention: No drug (Control)
Number of subjects: 150
Study: 16202020

Group type: EXPERIMENTAL
Intervention: Implementation of dental clinical practice guideline with multifaceted interventions (feedback, reminders, interactive meeting)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 0
Study: 12021826

Group type: EXPERIMENTAL
Intervention: Oxazepam
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Diazepam
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: IV Diazepam
Number of subjects: 0
Study: 10717746

Group type: EXPERIMENTAL
Intervention: Ivermectin alone (150-200 micrograms/kg)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Albendazole alone (400 mg)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Combination of ivermectin and albendazole
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study: 7854485

Group type: EXPERIMENTAL
Intervention: Atraumatic needle (pencil point, 22 gauge)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard needle (20 gauge)
Number of subjects: 100
Study: 1787609

Group type: EXPERIMENTAL
Intervention: CAF (cyclophosphamide, doxorubicin and 5‐fluorouracil)
Number of subjects: 69

Group type: COMPARATOR
Intervention: CMF (cyclophosphamide, methotrexate and 5‐fluorouracil)
Number of subjects: 69
Study: 7019839

Group type: EXPERIMENTAL
Intervention: Theophylline (250 mg fast release)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Terbutaline (2.5 mg)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Combination of Theophylline and Terbutaline
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Theophylline
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Terbutaline
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Theophylline or Terbutaline (alone or in combination)
Number of subjects: 21
Study: 30456780

Group type: EXPERIMENTAL
Intervention: Lipoxyderm™
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study: 28074556

Group type: EXPERIMENTAL
Intervention: Isavuconazole (therapeutic or supratherapeutic doses daily for 11 days after a 2-day loading dose)
Number of subjects: 161

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 161

Group type: COMPARATOR
Intervention: Moxifloxacin (400 mg q.d.)
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Isavuconazole (in phase III SECURE trial, n=257)
Number of subjects: 161
Study: 26621254

Group type: EXPERIMENTAL
Intervention: Chemoradiotherapy with cisplatin and 9 l of saline solution during hydration in the first, fourth, and seventh week
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control group receiving radiotherapy only
Number of subjects: 38
Study: 22521701

Group type: EXPERIMENTAL
Intervention: RelyX Veneer (RV) on Dentine (D)
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Variolink II (V2) on Dentine (D)
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Variolink Veneer (VV) on Dentine (D)
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Variolink Veneer (VV) on Enamel (E)
Number of subjects: 135
Study: 21135055

Group type: EXPERIMENTAL
Intervention: High-dose platinum-based chemotherapy (HD-PB)
Number of subjects: 230

Group type: COMPARATOR
Intervention: Conventional anthracycline-based chemotherapy
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Overall survival
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: BRCA1-like(CGH) tumours
Number of subjects: 230
Study: 19922250

Group type: EXPERIMENTAL
Intervention: Scalp acupuncture (SA) at left Sishencong (HN1), GB18, GB9, TH20 for 20 minutes
Number of subjects: 10

Group type: COMPARATOR
Intervention: Upper and lower limb acupuncture (ULLA) at right LI1, LI10, LV3, ST36 for 20 minutes
Number of subjects: 10
Study: 17089581

Group type: EXPERIMENTAL
Intervention: Two units of freshly collected cord blood transfusion
Number of subjects: 39

Group type: COMPARATOR
Intervention: Two units of adult blood transfusion
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Microalbuminuria assessment after one month of treatment
Number of subjects: 39
Study: 15587750

Group type: EXPERIMENTAL
Intervention: Right internal jugular group (G-RIJV)
Number of subjects: 272

Group type: EXPERIMENTAL
Intervention: Left subclavian group (G-LSCV)
Number of subjects: 272

Group type: COMPARATOR
Intervention: Right subclavian group (G-RSCV)
Number of subjects: 272

Group type: EXPERIMENTAL
Intervention: Left internal jugular vein group (G-LIJV)
Number of subjects: 272
Study: 11777489

Group type: EXPERIMENTAL
Intervention: Desogestrel (75 microg/day)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Levonorgestrel (30 microg/day)
Number of subjects: 81
Study: 9258415

Group type: EXPERIMENTAL
Intervention: Growth hormone replacement therapy (0.125 IU/kg per week for the first 4 weeks, then 0.25 IU/kg per week)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Growth hormone replacement therapy
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 8276025

Group type: EXPERIMENTAL
Intervention: Dopamine infusion at 5-15 micrograms/kg per min
Number of subjects: 40

Group type: COMPARATOR
Intervention: Dobutamine infusion at 5-15 micrograms/kg per min
Number of subjects: 40
Study: 3106656

Group type: EXPERIMENTAL
Intervention: Glyburide, 20 mg/d (plus insulin)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo (plus insulin)
Number of subjects: 16
Study: 30553231

Group type: EXPERIMENTAL
Intervention: Cranberry juice (500 mL/d)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control group (usual diet)
Number of subjects: 41
Study: 28986984

Group type: EXPERIMENTAL
Intervention: Component-resolved diagnosis (CRD) combined with clinical factors and sensitization patterns
Number of subjects: 423

Group type: EXPERIMENTAL
Intervention: Cor a 9 and Cor a 14 IgE levels
Number of subjects: 423

Group type: EXPERIMENTAL
Intervention: Cor a 1 IgE levels
Number of subjects: 423

Group type: EXPERIMENTAL
Intervention: Combination of Cor a 1 and Cor a 9
Number of subjects: 423

Group type: EXPERIMENTAL
Intervention: Model using atopic dermatitis, pollen allergy, IgE against Cor a 14, and walnut
Number of subjects: 423

Group type: EXPERIMENTAL
Intervention: Reported symptoms
Number of subjects: 423
Study: 27733375

Group type: EXPERIMENTAL
Intervention: Three preoperative cycles of epirubicin 120 mg/m2 and ifosfamide 9 g/m2 (Arm A)
Number of subjects: 328

Group type: COMPARATOR
Intervention: Five cycles of adjuvant chemotherapy (Arm B)
Number of subjects: 328

Group type: EXPERIMENTAL
Intervention: Overall group (both arms combined)
Number of subjects: 328

Group type: EXPERIMENTAL
Intervention: Three cycles of chemotherapy (Arm A)
Number of subjects: 328

Group type: COMPARATOR
Intervention: Five cycles of chemotherapy (Arm B)
Number of subjects: 328

Group type: EXPERIMENTAL
Intervention: Response to therapy
Number of subjects: 328
Study: 24946783

Group type: EXPERIMENTAL
Intervention: TimeSlips creative storytelling program
Number of subjects: 10
Study: 21504479

Group type: EXPERIMENTAL
Intervention: Immediate loading group
Number of subjects: 36

Group type: COMPARATOR
Intervention: Conventional loading group
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 36
Study: 20827218

Group type: EXPERIMENTAL
Intervention: Clinician-delivered HIV prevention training intervention
Number of subjects: 386

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 386
Study: 17042774

Group type: EXPERIMENTAL
Intervention: Desferrioxamine (Group A)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Deferiprone (Group B)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control (Group C)
Number of subjects: 16
Study: 15749318

Group type: EXPERIMENTAL
Intervention: Sterillium applied for 3 min
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Sterillium applied for 2 min
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Sterillium applied for 1.5 min
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Sterillium applied for 1 min
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Other preparations applied for 1 min
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Sterillium applied for 1.5 min (2 x 3 mL)
Number of subjects: 2
Study: 11867404

Group type: EXPERIMENTAL
Intervention: Epinephrine‐15 group (3 mL of 1.5% lidocaine containing 15 microg epinephrine)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Epinephrine‐10 group (2 mL of test dose)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Epinephrine‐5 group (1 mL of test dose)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Saline group (3 mL of normal saline IV)
Number of subjects: 80
Study: 10468074

Group type: EXPERIMENTAL
Intervention: Abciximab
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Eptifibatide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tirofiban
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 7781586

Group type: EXPERIMENTAL
Intervention: Hydroxyzine 25 mg at a daily dosage of 100 mg t.i.d. (25 mg - 25 mg - 50 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lorazepam 1 mg at a daily dosage of 4 mg t.i.d. (1 mg - 1 mg - 2 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hydroxyzine and Lorazepam (both groups)
Number of subjects: 0
Study: 2235209

Group type: EXPERIMENTAL
Intervention: Aerosolized ribavirin
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study: 361067

Group type: EXPERIMENTAL
Intervention: Salbutamol
Number of subjects: 88

Group type: COMPARATOR
Intervention: Ethanol
Number of subjects: 88
Study: 31475652

Group type: EXPERIMENTAL
Intervention: β-carotene supplementation
Number of subjects: 290

Group type: EXPERIMENTAL
Intervention: Gestational age at delivery
Number of subjects: 290

Group type: EXPERIMENTAL
Intervention: Anthropometric measures
Number of subjects: 290

Group type: EXPERIMENTAL
Intervention: Seasonal variation
Number of subjects: 290
Study: 31301621

Group type: EXPERIMENTAL
Intervention: Supported self-help preventive cognitive therapy (S-PCT)
Number of subjects: 248

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 248
Study: 28550023

Group type: EXPERIMENTAL
Intervention: FSH 75 IU
Number of subjects: 732

Group type: COMPARATOR
Intervention: CC 100 mg
Number of subjects: 732
Study: 24691248

Group type: EXPERIMENTAL
Intervention: Pursed-lip breathing (PLB)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control breathing (CB)
Number of subjects: 40
Study: 23363494

Group type: EXPERIMENTAL
Intervention: Pulmonary perfusion with oxygenated blood
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Custodiol HTK solution
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 90
Study: 21809048

Group type: EXPERIMENTAL
Intervention: 4-session telephone-delivered motivational interviewing (MI)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 1-session telephone-delivered motivational interviewing (MI)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (no MI)
Number of subjects: 0
Study: 19748405

Group type: EXPERIMENTAL
Intervention: Local manipulative therapy combined with exercise and soft tissue treatment
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Full kinetic chain manipulative therapy combined with exercise and soft tissue treatment
Number of subjects: 31
Study: 15627856

Group type: EXPERIMENTAL
Intervention: Brief Dynamic Therapy (BDT)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Brief Supportive Psychotherapy (BSP)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Waiting List Condition
Number of subjects: 30
Study: 12118806

Group type: EXPERIMENTAL
Intervention: Slow load amiodarone (7 g oral amiodarone more than 10 days starting 5 days before OHS; n = 56)
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Fast load amiodarone (6 g oral amiodarone more than 6 days starting 1 day before OHS; n = 64)
Number of subjects: 220

Group type: COMPARATOR
Intervention: Placebo (n = 100)
Number of subjects: 220
Study: 10403145

Group type: EXPERIMENTAL
Intervention: Paroxetine (20 mg/day for first 6 weeks, adjusted to 20-50 mg/day thereafter)
Number of subjects: 203

Group type: COMPARATOR
Intervention: Fluoxetine (20 mg/day for first 6 weeks, adjusted to 20-80 mg/day thereafter)
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 203

Group type: COMPARATOR
Intervention: Fluoxetine
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 203
Study: 7585063

Group type: EXPERIMENTAL
Intervention: Bromocriptine
Number of subjects: 2

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2
Study: 2129373

Group type: EXPERIMENTAL
Intervention: TPA (tissue plasminogen activator)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Immediate PTCA (percutaneous transluminal coronary angioplasty)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Routine interventional post-lytic care (PTCA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Acute administration of IV beta blocker (metoprolol)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Delayed administration of beta blocker (starting on Day 6)
Number of subjects: 0
Study: 7404301

Group type: EXPERIMENTAL
Intervention: 200 mg doxycycline and 2 g tinidazole (single preoperative dose)
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: 80 mg gentamicin and 600 mg clindamycin (three doses with eight hour intervals, starting one hour preoperatively)
Number of subjects: 145

Group type: COMPARATOR
Intervention: No antimicrobial agent (control group)
Number of subjects: 145
Study: 31939919

Group type: EXPERIMENTAL
Intervention: Cliradex (terpinen‐4‐ol) lid scrubs
Number of subjects: 50

Group type: COMPARATOR
Intervention: Sham lid scrubs
Number of subjects: 50
Study: 30981750

Group type: EXPERIMENTAL
Intervention: 'Paesaggi di Prevenzione' program
Number of subjects: 5061
Study: 28051876

Group type: EXPERIMENTAL
Intervention: Breastfeeding
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control (no breastfeeding)
Number of subjects: 100
Study: 26051455

Group type: EXPERIMENTAL
Intervention: Single dose of misoprostol
Number of subjects: 95
Study: 23812769

Group type: EXPERIMENTAL
Intervention: Single-dose intraoperative radiation therapy (IORT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: 6-week whole-breast external-beam radiation therapy (WB-EBRT)
Number of subjects: 0
Study: 21471093

Group type: EXPERIMENTAL
Intervention: Home testing with CPAP for 3 months
Number of subjects: 296

Group type: COMPARATOR
Intervention: In-laboratory testing with CPAP for 3 months
Number of subjects: 296
Study: 19545475

Group type: EXPERIMENTAL
Intervention: Escitalopram (10 mg)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 16707395

Group type: EXPERIMENTAL
Intervention: Allopurinol 300 mg daily for 2 weeks
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 16291351

Group type: EXPERIMENTAL
Intervention: Salbutamol inhalation
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control (baseline measurements)
Number of subjects: 41
Study: 12122921

Group type: EXPERIMENTAL
Intervention: NK1 receptor antagonists
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 10532692

Group type: EXPERIMENTAL
Intervention: Fish oil (n = 8)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo (n = 8)
Number of subjects: 16
Study: 7593698

Group type: EXPERIMENTAL
Intervention: Herbal-based toothpaste
Number of subjects: 70

Group type: COMPARATOR
Intervention: Conventional dentifrice
Number of subjects: 70
Study: 2284219

Group type: EXPERIMENTAL
Intervention: Lornoxicam 4 mg twice daily for 14 days
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Lornoxicam 4 mg, indomethacin 50 mg, or placebo twice daily for 29 days
Number of subjects: 45

Group type: COMPARATOR
Intervention: Indomethacin 50 mg twice daily for 29 days
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo twice daily for 29 days
Number of subjects: 45
Study: 7457801

Group type: EXPERIMENTAL
Intervention: Controlled mechanical ventilation, relaxation, intravenous anaesthesia, at least 1 1 fluid replacement, careful monitoring
Number of subjects: 13

Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 13
Study: 30025940

Group type: EXPERIMENTAL
Intervention: Cryotherapy (ice packs applied after surgery)
Number of subjects: 169
Study: 26970404

Group type: EXPERIMENTAL
Intervention: Intravenous esomeprazole (single-dose)
Number of subjects: 20
Study: 26677665

Group type: EXPERIMENTAL
Intervention: SGRS Chinese herbs as adjuvant therapy
Number of subjects: 84

Group type: COMPARATOR
Intervention: Controlled ovarian hyperstimulation (COH) and IVF‐ET
Number of subjects: 84
Study: 23013325

Group type: EXPERIMENTAL
Intervention: Prenatal alcohol exposure
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: Low-to-moderate levels of alcohol exposure
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: Monthly alcohol consumption by mothers
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: Alcohol abuse/dependence with ≥ 4 drinks/occasion
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: Lower prepregnancy weight of mothers
Number of subjects: 480
Study: 22198102

Group type: EXPERIMENTAL
Intervention: Combination of 100 mg aspirin and 200 mg cilostazol
Number of subjects: 54
Study: 18204334

Group type: EXPERIMENTAL
Intervention: Aripiprazole (2 mg/d, titrated to a maximum of 30 mg/d at day 28)
Number of subjects: 295

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 295

Group type: EXPERIMENTAL
Intervention: Aripiprazole
Number of subjects: 295
Study: 16311188

Group type: EXPERIMENTAL
Intervention: Isokinetic device flexing and extending the left knee at 30 degrees/s, 60 degrees/s, and 120 degrees/s
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Selective dorsal rhizotomy
Number of subjects: 25
Study: 12562459

Group type: EXPERIMENTAL
Intervention: Peppermint oil (90 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Caraway oil (50 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Cisapride (10 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: n-butylscopolamine (10 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 10986569

Group type: EXPERIMENTAL
Intervention: Discharged patients moved to highly supervised settings (professionally supervised group homes, supervised hostels, foster families).
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Discharged patients (20%) went to nursing homes due to loss of autonomy from physical disorders.
Number of subjects: 192

Group type: COMPARATOR
Intervention: Inpatients remaining in the hospital.
Number of subjects: 192
Study: 8636675

Group type: EXPERIMENTAL
Intervention: Presence of a medical student
Number of subjects: 34

Group type: COMPARATOR
Intervention: No medical student present
Number of subjects: 34
Study: 1460195

Group type: EXPERIMENTAL
Intervention: Piroxicam
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study: 6324586

Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (20 cc/kg weekly doses before and after transplantation)
Number of subjects: 36
Study: 30357404

Group type: EXPERIMENTAL
Intervention: Comprehensive childhood-obesity intervention
Number of subjects: 929
Study: 28792851

Group type: EXPERIMENTAL
Intervention: High-intensity interval training (HIIT)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Moderate-intensity continuous training (MICT)
Number of subjects: 17
Study: 25533447

Group type: EXPERIMENTAL
Intervention: Palonosetron (0.75 mg on day 1)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Granisetron (3 mg twice daily on days 1 through 5)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Combination antiemetic therapy (5‐HT3 receptor antagonists, NK‐1RAs, and dexamethasone)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Consecutive‐day granisetron
Number of subjects: 24
Study: 24146218

Group type: EXPERIMENTAL
Intervention: Neoadjuvant capecitabine and oxaliplatin (CAPOX) and chemoradiotherapy (CRT) with cetuximab
Number of subjects: 164

Group type: COMPARATOR
Intervention: Neoadjuvant capecitabine and oxaliplatin (CAPOX) and chemoradiotherapy (CRT) without cetuximab
Number of subjects: 164
Study: 20689518

Group type: EXPERIMENTAL
Intervention: Subcutaneous rEPO at 250 units kg(‐1) per dose, three times weekly for 6 weeks
Number of subjects: 119

Group type: COMPARATOR
Intervention: Subcutaneous rEPO at 750 units kg(‐1) per dose, once weekly for 6 weeks
Number of subjects: 119
Study: 19004650

Group type: EXPERIMENTAL
Intervention: Simultaneous hand cold stimulation
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Simultaneous foot cold stimulation
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Tonic rectal electrical stimulation
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Tonic rectal distension stimulation
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Heterotopic stimulation (hand and foot)
Number of subjects: 15
Study: 16933087

Group type: EXPERIMENTAL
Intervention: High fidelity Integrated Dual Disorders Treatment program
Number of subjects: 182

Group type: COMPARATOR
Intervention: Service as usual
Number of subjects: 182